Examining the link between red blood cell size variability and blood sugar control in type 2 diabetes patients
Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control
This study is testing if changes in red blood cell size can help doctors understand and manage blood sugar levels better in people with uncontrolled type 2 diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | New Valley University Academic / other |
| Locations | 1 site (Al Khārjah) |
| Trial ID | NCT06067399 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between red cell distribution width (RDW) and glycated hemoglobin (HbA1C) levels in patients with uncontrolled type 2 diabetes mellitus (T2DM). By analyzing complete blood count parameters, particularly RDW, the study aims to identify potential prognostic markers that could help in monitoring and managing diabetes-related complications. The research focuses on patients with HbA1C levels greater than 7%, excluding those with type 1 diabetes or other conditions that may affect RDW. The findings could provide insights into the role of RDW in diabetes management and its association with disease complications.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with uncontrolled type 2 diabetes mellitus, specifically those with HbA1C levels above 7%.
Not a fit: Patients with type 1 diabetes, secondary diabetes, or conditions that significantly alter RDW will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the monitoring and management of type 2 diabetes by identifying RDW as a useful prognostic marker.
How similar studies have performed: Previous studies have explored the relationship between RDW and various diseases, including diabetes, but results have been inconsistent, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%) Exclusion Criteria: 1. Patients diagnosed to have type 1 diabetes. 2. Patients are diagnosed to have secondary diabetes. 3. Clinical states associated with increased RDW: * Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate. * After blood transfusions * Pregnancy, thrombotic thrombocytopenic purpura and inflammatory bowel disease.
Where this trial is running
Al Khārjah
- New Valley University- Faculty of Medicine — Al Khārjah, Egypt (Recruiting)
Study contacts
- Study coordinator: Asmaa N Hussein, MD
- Email: asmaanady_1010@med.nvu.edu.eg
- Phone: 01065161752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.